Sangamo Therapeutics Inc
(LTS:0R1D)
$
0.43
0.0278 (6.91%)
Market Cap: 87.40 Mil
Enterprise Value: 63.80 Mil
PE Ratio: 0
PB Ratio: 1.52
GF Score: 38/100 - Q4 2023 Sangamo Therapeutics Inc Earnings Call TranscriptMar 13, 2024$0.8008 (-5.87%)Earnings
- Q3 2023 Sangamo Therapeutics Inc Earnings Call TranscriptNov 02, 2023$0.4755 (-13.97%)Earnings
- Q2 2023 Sangamo Therapeutics Inc Earnings Call TranscriptAug 08, 2023$1.14 (-2.56%)Earnings
- Sangamo Therapeutics Inc at Barclays Virtual Gene Editing & Therapy Summit TranscriptMay 24, 2023
- Sangamo Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Sangamo Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q1 2023 Sangamo Therapeutics Inc Earnings Call TranscriptApr 27, 2023$1.66 (+3.99%)Earnings
- Sangamo Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Q4 2022 Sangamo Therapeutics Inc Earnings Call TranscriptFeb 22, 2023$2.92Earnings
- Sangamo Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptDec 01, 2022
- Sangamo Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Q3 2022 Sangamo Therapeutics Inc Earnings Call TranscriptNov 03, 2022$4.26 (-3.60%)Earnings
- Q2 2022 Sangamo Therapeutics Inc Earnings Call TranscriptAug 04, 2022$4.78Earnings
- Sangamo Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Sangamo Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptMay 24, 2022
- Sangamo Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Q1 2022 Sangamo Therapeutics Inc Earnings Call TranscriptMay 05, 2022$4.35 (+1.83%)Earnings
- Sangamo Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 17, 2022
- Q4 2021 Sangamo Therapeutics Inc Earnings Call TranscriptFeb 24, 2022$5.44 (-1.31%)Earnings
- Sangamo Therapeutics Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- Q3 2021 Sangamo Therapeutics Inc Earnings Call TranscriptNov 04, 2021$11.03 (+20.41%)Earnings
- Sangamo Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2021
- Q2 2021 Sangamo Therapeutics Inc Earnings Call TranscriptAug 05, 2021$9.76 (+1.99%)Earnings
- Sangamo Therapeutics Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 04, 2021
- Sangamo Therapeutics Inc Annual Shareholders Meeting TranscriptMay 25, 2021
- Sangamo Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) TranscriptMay 18, 2021
- Sangamo Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Q1 2021 Sangamo Therapeutics Inc Earnings Call TranscriptMay 04, 2021$11.3 (-4.48%)Earnings
- Sangamo Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Sangamo Therapeutics Inc at H C Wainwright Global Life Sciences Conference (Virtual) TranscriptMar 09, 2021
- Q4 2020 Sangamo Therapeutics Inc Earnings Call TranscriptFeb 24, 2021$12.57 (+6.24%)Earnings
- Sangamo Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Sangamo Therapeutics Inc at Barclays Virtual Gene Editing & Gene Therapy Summit TranscriptNov 16, 2020
- Sangamo Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 09, 2020
- Q3 2020 Sangamo Therapeutics Inc Earnings Call TranscriptNov 04, 2020$10.43Earnings
- Sangamo Therapeutics Inc at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2020
- Sangamo Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 18, 2020
- Q2 2020 Sangamo Therapeutics Inc Earnings Call TranscriptAug 05, 2020$10.58Earnings
- Sangamo Therapeutics Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 02, 2020
- Sangamo Therapeutics Inc Annual Shareholders Meeting TranscriptMay 18, 2020
- Sangamo Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Q1 2020 Sangamo Therapeutics Inc Earnings Call TranscriptMay 11, 2020$7.27Earnings
- Sangamo Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 11, 2020
- Q4 2019 Sangamo Therapeutics Inc Earnings and Collaboration Agreement with Biogen Inc Call TranscriptFeb 28, 2020
- Sangamo Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Sangamo Therapeutics Inc R&D Day TranscriptDec 17, 2019
- Q3 2019 Sangamo Therapeutics Inc Earnings Call TranscriptNov 06, 2019$9.07Earnings
- Sangamo Therapeutics Inc at Jefferies Gene Therapy/Editing Summit TranscriptOct 08, 2019
- Sangamo Therapeutics Inc at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Q2 2019 Sangamo Therapeutics Inc Earnings Call TranscriptAug 07, 2019$12.17Earnings
- Sangamo Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 15, 2019
- Q1 2019 Sangamo Therapeutics Inc Earnings Call TranscriptMay 08, 2019$13.28Earnings
- Sangamo Therapeutics Inc Clinical Development Update Call TranscriptApr 02, 2019
- Sangamo Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2019
- Q4 2018 Sangamo Therapeutics Inc Earnings Call TranscriptFeb 28, 2019$9.11Earnings
Sangamo Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2022 / 01:00PM GMT
Release Date Price:
$4.21
(+0.24%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to introduce Sandy Macrae, the CEO of Sangamo. Thanks so much for joining us today, Sandy.
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
A pleasure to be with you.
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
And for those who may be new to the story, can you provide a 1-minute intro, highlighting your main products and key catalysts.
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
Delighted to do so. So we have compelling story of clinical products and a remarkable future to come. We're going to talk, I'm sure, about our 3 clinical phase assets, which are either in Phase III or about to go into Phase III in the coming year. We have fabry disease wholly owned with really interesting data that I think is a leading
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)